vedolizumab

Type: Keyphrase
Name: vedolizumab
First reported 20 hours ago - Updated 20 hours ago - 1 reports

EMA: 39 human-use drug OKs in first-half 2014

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended 39 human-use medicines for marketing authorisation in first-half 2014, compared to 44 in the same period of 2013 and 33 in first-half 2012. However, ... [Published Pharma Times - 20 hours ago]
First reported Jul 09 2014 - Updated Jul 09 2014 - 2 reports

Takeda's Entyvio available in UK for UC and Crohn's

UK patients with ulcerative colitis and Crohn's disease can now potentially get access to Takeda UK's Entyvio following the drug's launch in the country.In May, Entyvio (vedolizumab) became the first and only biologic therapy to be approved in Europe ... [Published Pharma Times - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 2 reports

Treatment for ulcerative colitis and Crohn’s disease launched

A new drug treatment for ulcerative colitis and Crohn’s disease has been launched in the UK.Vedolizumab is a gut-selective integrin antagonist, marketed as Entyvio by Takeda UK. It will be used to treat patients with active ulcerative colitis or active ... [Published Pharmacy Magazine - Jul 08 2014]
First reported Jun 24 2014 - Updated Jun 24 2014 - 1 reports

TAKEDA - Challenges Ahead for its New European President

Research and Markets (http://www.researchandmarkets.com/research/8r4g3k/takeda) has announced the addition of the "" company profile to their offering. Post Nycomed and Millenium acquisition, the new leadership of non-Japanese CEO/President Mr. Weber ... [Published Individual.com - Jun 24 2014]
First reported Jun 20 2014 - Updated Jun 20 2014 - 1 reports

Takeda drops prostate cancer drug in phase III

Takeda has suffered another blow to its late-stage pipeline after calling time on orteronel (TAK-700) for prostate cancer after disappointing phase III data. The Japanese pharma company said it decided to discontinue the programme in metastatic, castration-resistant ... [Published PMLive - Jun 20 2014]
First reported Jun 16 2014 - Updated Jun 16 2014 - 2 reports

ENTYVIO™ (vedolizumab) Now Available in the United States for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis and Crohn's Disease

DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of ... [Published PR Newswire: General Business - Jun 16 2014]
First reported Jun 02 2014 - Updated Jun 02 2014 - 1 reports

FDA Approves Takeda's Entyvio? vedolizumab for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

By a News Reporter-Staff News Editor at Clinical Trials Week Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., announced that the United States (U.S.) Food and Drug Administration (FDA) ... [Published Pharmacy Choice - Jun 02 2014]
First reported May 26 2014 - Updated May 28 2014 - 2 reports

Takeda Receives European Commission Marketing Authorisation for Entyvio(R) (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease

Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ... [Published PRESSEMITTEILUNGEN - May 27 2014]
First reported May 23 2014 - Updated May 23 2014 - 1 reports

ENTYVIO (Vedolizumab) Injection, Powder, Lyophilized, For Solution [Takeda Pharmaceuticals America, Inc.]

First reported May 20 2014 - Updated May 21 2014 - 3 reports

Takeda's Entyvio gets FDA approval to treat ulcerative colitis, Crohn's disease

Japan-based Takeda Pharmaceutical Company (Takeda) and its wholly-owned subsidiary Takeda Pharmaceuticals USA have received approval from the US Food and Drug Administration (FDA) for a new biologic therapy, Entyvio (vedolizumab), to treat adults with ... [Published PBR - News - May 21 2014]
First reported May 20 2014 - Updated May 21 2014 - 2 reports

FDA Approves Takeda's Entyvio™ (vedolizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

DEERFIELD, Ill. and OSAKA, Japan, May 20, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced that the United States (U.S.) Food and Drug Administration ... [Published PR Newswire: Policy & Public Interest - May 20 2014]
First reported Apr 21 2014 - Updated Apr 21 2014 - 1 reports

For Treatment of Ulcerative Colitis (UC), Great Opportunity Exists for Vedolizumab in the U.S. and EU5 Market, Owing to its Novel Mechanism of Action and Promising Efficacy

BURLINGTON, Mass., April 21, 2014 /PRNewswire/ -- Decision Resources Group finds that, according to surveyed U.S. and EU5 gastroenterologists, effect on mucosal healing and improvement in the maintenance of remission are two of the attributes that ... [Published PR Newswire: General Business - Apr 21 2014]
Entities: vedolizumab, Action, Market

Quotes

...to discontinue the programme in metastatic, castration-resistant prostate cancer (CRPC) after deciding that orteronel's clinical profile was not "sufficient to move forward … given the availability of other therapies"
Takeda now says it has concluded a "detailed investigation of these reactions [which] confirmed no quality or manufacturing issues were present."
"Surgery doesn't cure Crohn's," Dr. Sartor said, "but this technique preserves most of the natural function of the small intestine, where nutrients are absorbed."
...healthcare professionals who care for them, need additional new treatment options," said Douglas Cole, president, Takeda Pharmaceuticals U S A Inc. "Entyvio reflects an expansion of Takeda's commitment to supporting patients with gastrointestinal disorders."

More Content

All (41) | News (25) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
EMA: 39 human-use drug OKs in first-half 2014 [Published Pharma Times - 20 hours ago]
Takeda's Entyvio available in UK for UC and Cro... [Published Pharma Times - Jul 09 2014]
Gut reaction [Published Drug Discovery News - Jul 09 2014]
Takeda's Entyvio available in UK for ulcerative... [Published Pharma Times - Jul 08 2014]
Treatment for ulcerative colitis and Crohn’s di... [Published Pharmacy Magazine - Jul 08 2014]
Treatment for ulcerative colitis and Crohn’s di... [Published PJ Online - Jul 08 2014]
TAKEDA - Challenges Ahead for its New European ... [Published Individual.com - Jun 24 2014]
Takeda drops prostate cancer drug in phase III [Published PMLive - Jun 20 2014]
Global crohn's disease market forecast to total... [Published PR inside - Jun 17 2014]
Entyvio available in US for treating ulcerative... [Published Orthopedics Today - Jun 16 2014]
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
Omontys terminal as Takeda switches off support [Published PMLive - Jun 16 2014]
Human medicines European public assessment repo... [Published European Medicines Agency - Jun 16 2014]
Takeda Launches Ulcer FDC Tablets In Japan [Published Pharmaceutical Online - Jun 13 2014]
Advances in treating bowel disease [Published Buffalo News - Jun 07 2014]
May's top stories: Bayer's $14.2bn Merck deal, ... [Published Pharmaceutical Technology - Jun 06 2014]
Approval of Takeda’s Entyvio marks “historic ch... [Published Pharma Letter - Jun 03 2014]
New Help for Those With Crohn's, Colitis [Published NewsMax.com - Jun 02 2014]
FDA Approves Takeda's Entyvio? vedolizumab for ... [Published Pharmacy Choice - Jun 02 2014]
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Takeda's Entyvio gets FDA approval to treat ulc... [Published PBR - News - May 21 2014]
Entyvio Approved for Ulcerative Colitis and Cro... [Published Yahoo! Health News - May 21 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published PR Newswire: Policy & Public Interest - May 20 2014]
FDA Approves Takeda's Entyvio™ (vedolizumab) fo... [Published Nycomed News RSS feed - May 20 2014]
Takeda's Entyvio Wins FDA OK for Severe Colitis [Published MedPageToday.com - medical news plus CME for ph ... - May 20 2014]
For Treatment of Ulcerative Colitis (UC), Great... [Published PR Newswire: General Business - Apr 21 2014]
EMA committee issues positive opinion for Taked... [Published Pharmaceutical Business Review - Mar 24 2014]
Takeda Receives Positive CHMP Opinion for Entyv... [Published Nycomed News RSS feed - Mar 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
ENTYVIO™ (vedolizumab) Now Available in the Uni... [Published PR Newswire: General Business - Jun 16 2014]
DEERFIELD, Ill., and OSAKA, Japan, June 16, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced the United States (U.S.) commercial availability of ...
Takeda Receives European Commission Marketing A... [Published PRESSEMITTEILUNGEN - May 27 2014]
Zurich And Osaka, Japan (ots/PRNewswire) – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing Authorisation for Entyvio(R) ...
Takeda Receives European Commission Marketing A... [Published Nycomed News RSS feed - May 26 2014]
Zurich, Switzerland, May 27th, 2014 and Osaka, Japan, May 28th, 2014 – Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals International GmbH, today announced that the European Commission (EC) has granted Marketing ...
ENTYVIO (Vedolizumab) Injection, Powder, Lyophi... [Published DailyMed Drug Label Updates for the last seven ... - May 23 2014]
Updated Date: May 23, 2014 EST ...
Takeda's Entyvio gets FDA approval to treat ulc... [Published PBR - News - May 21 2014]
Japan-based Takeda Pharmaceutical Company (Takeda) and its wholly-owned subsidiary Takeda Pharmaceuticals USA have received approval from the US Food and Drug Administration (FDA) for a new biologic therapy, Entyvio (vedolizumab), to treat adults with ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.